Perrigo Buys Rosemont Pharma For $283m
Perrigo Co, a maker of generic and over-the-counter drugs, announced today that it bought UK-based Rosemont Pharmaceuticals for approximately $283 million in cash to gain access to Rosemont's oral liquid formulations business.
The deal is expected to add 8 cents to Perrigo's adjusted earnings per share for the remainder of fiscal 2013, Perrigo said in a statement.
Perrigo now expects fiscal 2013 adjusted earnings of $5.53 to $5.73 per share.
Source: Reuters
Featured Articles
NTT and medical technology company Olympus put on a demonstration, showing the IOWN APN's low-latency capability, for the first cloud endoscopy system
Richter BioLogics GmbH & Co KG's a new biopharmaceutical GMP facility in Germany will boost production capabilities and local employment
A pilot study from GE Healthcare has shown the value of Portrait Mobile Continuous Monitoring Solution, a leap in post-surgical monitoring efficiency